Aurora Cannabis (ACB) Competitors $4.03 -0.26 (-6.06%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACB vs. MLYS, NRIX, VIR, NTLA, COLL, RCUS, RCKT, XNCR, ZYME, and XERSShould you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), Zymeworks (ZYME), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Aurora Cannabis vs. Mineralys Therapeutics Nurix Therapeutics Vir Biotechnology Intellia Therapeutics Collegium Pharmaceutical Arcus Biosciences Rocket Pharmaceuticals Xencor Zymeworks Xeris Biopharma Aurora Cannabis (NASDAQ:ACB) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Do analysts rate ACB or MLYS? Mineralys Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 143.90%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ACB or MLYS? In the previous week, Mineralys Therapeutics had 12 more articles in the media than Aurora Cannabis. MarketBeat recorded 14 mentions for Mineralys Therapeutics and 2 mentions for Aurora Cannabis. Mineralys Therapeutics' average media sentiment score of 0.78 beat Aurora Cannabis' score of 0.35 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ACB or MLYS? 47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in ACB or MLYS? Aurora Cannabis received 365 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote. CompanyUnderperformOutperformAurora CannabisOutperform Votes38459.63% Underperform Votes26040.37% Mineralys TherapeuticsOutperform Votes19100.00% Underperform VotesNo Votes Which has more volatility & risk, ACB or MLYS? Aurora Cannabis has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Which has higher earnings and valuation, ACB or MLYS? Aurora Cannabis has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$320.81M0.75-$48.62M$0.0585.80Mineralys TherapeuticsN/AN/A-$177.81M-$3.64-3.72 Is ACB or MLYS more profitable? Aurora Cannabis has a net margin of 0.42% compared to Mineralys Therapeutics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.59% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis0.42% 0.59% 0.42% Mineralys Therapeutics N/A -67.97%-62.40% SummaryAurora Cannabis beats Mineralys Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get Aurora Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACB vs. The Competition Export to ExcelMetricAurora CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$241.16M$1.17B$5.53B$7.50BDividend YieldN/AN/A4.86%4.04%P/E Ratio85.829.6223.2218.08Price / Sales0.755.81363.0886.83Price / Cash26.3510.4038.1634.64Price / Book0.521.156.493.99Net Income-$48.62M-$56.07M$3.21B$247.18M7 Day Performance-3.16%-6.15%-4.91%-4.25%1 Month Performance-10.25%-12.63%-0.08%-6.87%1 Year Performance-39.24%-47.17%6.40%-3.73% Aurora Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACBAurora Cannabis0.283 of 5 stars$4.03-6.1%N/A-40.5%$226.54M$320.81M80.621,340Gap DownMLYSMineralys Therapeutics2.9598 of 5 stars$16.17-4.1%$27.00+67.0%+4.9%$1.02BN/A-4.4428Analyst ForecastInsider TradeHigh Trading VolumeNRIXNurix Therapeutics1.8249 of 5 stars$13.34+2.7%$30.88+131.5%-28.0%$1.01B$54.55M-4.62300Upcoming EarningsAnalyst ForecastNews CoverageGap DownVIRVir Biotechnology3.5078 of 5 stars$7.20+3.9%$35.67+395.4%-38.5%$987.43M$63.71M-1.84580Gap DownNTLAIntellia Therapeutics4.3406 of 5 stars$9.31+3.4%$37.56+303.4%-72.4%$963.74M$57.88M-1.71600Gap DownCOLLCollegium Pharmaceutical3.933 of 5 stars$30.56+1.7%$43.60+42.7%-26.4%$962.21M$631.45M13.17210RCUSArcus Biosciences2.1218 of 5 stars$9.15+2.3%$30.25+230.8%-59.5%$961.49M$258M-2.90500RCKTRocket Pharmaceuticals4.5547 of 5 stars$8.73+3.6%$43.00+392.6%-78.1%$930.88MN/A-3.17240News CoverageGap DownXNCRXencor3.5922 of 5 stars$12.95-1.9%$34.38+165.4%-58.6%$912.48M$110.49M-4.05280Gap DownZYMEZymeworks2.3552 of 5 stars$13.05+2.6%$21.00+60.9%+22.0%$907.98M$76.30M-8.70460Insider TradePositive NewsGap DownXERSXeris Biopharma4.3061 of 5 stars$5.87+1.0%$5.92+0.8%+134.6%$903.63M$203.07M-13.04290Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Nurix Therapeutics Competitors Vir Biotechnology Competitors Intellia Therapeutics Competitors Collegium Pharmaceutical Competitors Arcus Biosciences Competitors Rocket Pharmaceuticals Competitors Xencor Competitors Zymeworks Competitors Xeris Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACB) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurora Cannabis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurora Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
